Artificial intelligence in drug discovery: recent advances and future perspectives

José Jiménez-Luna (Corresponding author), Francesca Grisoni, Nils Weskamp, Gisbert Schneider

Research output: Contribution to journalArticleAcademicpeer-review

231 Citations (Scopus)
574 Downloads (Pure)

Abstract

Introduction: Artificial intelligence (AI) has inspired computer-aided drug discovery. The widespread adoption of machine learning, in particular deep learning, in multiple scientific disciplines, and the advances in computing hardware and software, among other factors, continue to fuel this development. Much of the initial skepticism regarding applications of AI in pharmaceutical discovery has started to vanish, consequently benefitting medicinal chemistry.Areas covered: The current status of AI in chemoinformatics is reviewed. The topics discussed herein include quantitative structure-activity/property relationship and structure-based modeling, de novo molecular design, and chemical synthesis prediction. Advantages and limitations of current deep learning applications are highlighted, together with a perspective on next-generation AI for drug discovery.Expert opinion: Deep learning-based approaches have only begun to address some fundamental problems in drug discovery. Certain methodological advances, such as message-passing models, spatial-symmetry-preserving networks, hybrid de novo design, and other innovative machine learning paradigms, will likely become commonplace and help address some of the most challenging questions. Open data sharing and model development will play a central role in the advancement of drug discovery with AI.

Original languageEnglish
Pages (from-to)949-959
Number of pages11
JournalExpert Opinion on Drug Discovery
Volume16
Issue number9
Early online date2 Apr 2021
DOIs
Publication statusPublished - Sept 2021
Externally publishedYes

Funding

This work was financially supported by the ETH RETHINK initiative, the Swiss National Science Foundation (grant no. 205321_182176), and Boehringer Ingelheim Pharma GmbH & Co. KG.

FundersFunder number
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung205321_182176

    Keywords

    • artificial intelligence
    • de novo drug design
    • Drug discovery
    • QSAR
    • synthesis prediction
    • Artificial Intelligence
    • Humans
    • Drug Design
    • Drug Discovery
    • Machine Learning
    • Quantitative Structure-Activity Relationship

    Fingerprint

    Dive into the research topics of 'Artificial intelligence in drug discovery: recent advances and future perspectives'. Together they form a unique fingerprint.

    Cite this